Daxor Corporation to Exhibit at the Society of Hospital Medicine (SHM) Annual Conference 2019
NEW YORK , March 22, 2019 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR) an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement today announces it will be exhibiting at the Annual Meeting of the Society of Hospital Medicine (SHM) being held at the Gaylord National Resort & Convention Center in National Harbor, MD from March 24-27, 2019.
“Hospitalists are responsible for reducing readmissions and improving outcomes for inpatients. The SHM Annual Conference is an excellent opportunity to generate awareness and educate hospitalists about the significant benefits of direct and objective measurement of intravascular blood volume, red blood cell volume and plasma volume via a simple blood test with Daxor’s BVA-100® Blood Volume Analyzer. Peer-reviewed studies have proven that optimization of intravascular blood volume improves outcomes, shortens length of stay, and can reduce mortality by up to 66% versus conventional therapy in complex critically-ill, and reduced 30-day mortality by 82%, 30-day readmissions by 56%, and 1-year mortality by 86% in heart failure patients. We look forward to sharing these compelling outcomes with the leaders in the field of hospital medicine,” said Michael Feldschuh, CEO of Daxor. The Company will be located at booth # 1109 in the main exhibition hall.
About Daxor Corporation
Daxor Corporation is an innovative medical instrumentation and biotechnology company. We manufacture the BVA-100 Blood Volume Analyzer, the first instrument cleared by the FDA to provide rapid direct measurement of a patient’s blood volume. We believe that the BVA-100 Blood Volume Analyzer has the potential to transform therapy in a broad range of surgical and medical conditions. It is our goal, working in conjunction with hospitals and clinics, to achieve that possibility. Ultimately the company’s mission is to help hospitals and physicians incorporate Daxor’s BVA-100 diagnostic into standard clinical practice. For more information please visit our website at http://www.daxor.com.
Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations Contact:Bret ShapiroSr. Managing PartnerCORE IR561-479-8566 firstname.lastname@example.org